During unsettling Covid-19 times of emergency, Dr. Ariel Beresniak puts science back to its rightful place as a benchmark for decision-making, in this article published in Causeur magazine on 4th May 2020.
Amid Covid-19 uncertainty, Dr. Ariel Beresniak was interviewed in this article by Corse Matin on Representative Seroprevalence Study.
Test-and-treat strategy using Urea Breath Tests is cost-effective in managing symptoms and consequences from Helicobacter Pylori infection
Test-and-treat strategy using Urea Breath Tests is proven to be cost-effective in managing symptoms and consequences from Helicobacter pylori infection, thus contributing to preventing peptic ulcer and gastric cancer.
For more information regarding this subject please refer to our Press Release.
USING UREA BREATH TESTS IS PROVEN TO BE A COST-EFFECTIVE METHOD FOR MANAGING SYMPTOMS AND CONSEQUENCES OF HELICOBACTER PYLORI BACTERIA INFECTION
Almost 60% of the world population is infected with the Helicobacter pylori bacteria: a new study establishes that a test-and-treat strategy using Urea Breath Tests is cost-effective in managing symptoms and consequences from this infection, thus contributing to prevent peptic ulcer and gastric cancer.
Helicobacter pylori infection is a major public health issue affecting 60% of the world’s population with 90% of Peptic Ulcer attributed to and 80% of Gastric Cancers associated with Hp infection.
With the support of an international expert panel composed of […]
Dr Ariel Beresniak took part in the Ethics Prize Seminar in Stockholm in October 2016, where he discussed once again how inadequate, inaccurate and unethical the QALY approach is when used for making a decision about new medicines’ access to patients in need.
This seminar was organised by the Swedish Council of Medical Ethics.
The full seminar broadcast can be viewed here. Dr Ariel Beresniak’s presentation starts at 1:50:13.
More information on the QALYs and DMI’s role in the ECHOUTCOME project: www.echoutcome.eu.
The European research project Electronic Health Records for Clinical Research (EHR4CR) was co-funded by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) under the Innovative Medicines Initiative. A new budgetary impact assessment published in the Journal of Health & Medical Informatics reveals that compared to current practices, the EHR4CR platform appears cost-saving for pharmaceutical industry, the primary sponsor of clinical trials.
The full article is available here.
More information on the EHR4CR project: www.ehr4cr.eu.
Public Health promoted by Classical Music – a concert-conference hosted by DMI in the frame of the ASSET project
It is a well-known fact how music positively affects the intellectual development and improves the concentration. This relationship, appreciated by musicians and music fans is gradually gaining more attention also from the scientific research teams around the world. The scientific consortium ASSET, financed by the European Commission, proposes a unique way of integrating classical music in the promotion of public health by organising a piano concert where the classical piano pieces will be accompanied by the presentations of six international scientific experts.
“Concerto for Piano and Sciences” is the first event of this kind […]